Cartherics to present at ThymOz 2023

Cartherics will be presenting at the ThymOZ 2023 International Conference on T Cells to be held from 22 -26 March at Heron Island in Queensland, Australia. The conference covers a broad range of topics including T cell differentiation and function, stromal cell biology, immunotherapy and tissue regeneration.

Rachelle Duffin, PhD Candidate at Cartherics will be presenting […]

2023-03-22T09:32:06+11:00March 22nd, 2023|

Cartherics to present at prestigious oncology conference in France

Cartherics is pleased to announce that Dr Vera Evtimov, Project Manager and Principal Scientist, will be presenting her work in ovarian cancer research at the European Society for Medical Oncology Targeted Anticancer Therapies Congress, ESMO TAT 2023, in Paris this March.

ESMO TAT, known as “The Home of Phase I in Oncology”, is the leading […]

2023-03-03T11:33:15+11:00March 3rd, 2023|

Cartherics to present at Australia Biologics 2023

Cartherics is pleased to announce that Dr Madeline Cao, Research Fellow, will be presenting at Australia Biologics 2023 at Crown Promenade, Melbourne.

The Australia Biologics Festival 2023 is Australia’s premier conference that aims to gather the innovators, pioneers, leaders in the biologics fraternity including biologics, biosimilars, vaccines, cell and gene therapy (CGT) and evolving therapeutics […]

2023-02-28T16:12:33+11:00February 28th, 2023|

Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Ovarian Cancer

Melbourne, Victoria, Australia 27 February 2023

Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer.

The clinical trial to be conducted by Peter Mac will be the first […]

2023-02-27T14:37:49+11:00February 27th, 2023|

Cartherics is ‘Turning Teal’ this February in support of ovarian cancer

Cartherics is delighted to be hosting a Teal Tea this February to raise awareness and funds for people affected by ovarian cancer.

Ovarian Cancer Australia’s Teal Ribbon Day is an initiative that aims to start conversations that change lives. It will increase awareness of the disease and help raise funds to support people affected by […]

2023-02-22T17:33:54+11:00February 22nd, 2023|

Cartherics celebrates PhD student’s success

Cartherics is delighted to announce that Saleh Almasabi has successfully completed his PhD Candidature.

Saleh’s research thesis, The role of integrin linked kinase in senescence and immunosuppressive tumor microenvironment in colon cancer’, identified that integrin-linked kinase (ILK) is associated with cancer prognosis and characterises the immunosuppressive tumor microenvironment. These findings suggest possible clinical avenues of targeting […]

2023-02-06T13:37:22+11:00February 6th, 2023|

CGTLive Interview: New Frontiers in Allogeneic Cell Therapy

Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours.

Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ovarian, […]

2023-02-01T11:57:58+11:00January 20th, 2023|

Cartherics granted first patent in China for multiple development candidates

Melbourne, Australia, 09 January 2023Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent filing WO2017088012.

The […]

2023-01-09T14:10:25+11:00January 9th, 2023|

Cartherics to Present at Biotech Showcase™ 2023

Cartherics to Present at Biotech Showcase™ 2023

Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program at Biotech Showcase, with a view to engaging with potential investors and partners

Melbourne, Australia, 22 December 2022Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it […]

2023-01-27T11:50:03+11:00December 22nd, 2022|

Message from the CEO – December 2022

This year has been an exciting and productive one for Cartherics. We opened our new and impressive research and development facility in Notting Hill and are busy completing the preclinical studies for our lead iNK product for treating ovarian cancer. The follow-on product pipeline is revving up with new CAR target candidates, additional gene edits […]

2023-01-20T12:22:20+11:00December 14th, 2022|
Go to Top